ATUAÇÃO DO FARMACEUTICO NA ORIENTAÇÃO AO USO DA TOXINA BOTULÍNICA

Abstract

The increase in life expectancy in the country has collectively attracted greater attention by the population, and their well-being, including self-esteem and body and facial aesthetics. In addition, there is also the search for the so-called standards of beauty imposed by society. According to annual data from the International Society of Aesthetic Plastic Surgery (ISAPS) in 2017, Brazil was the third country in the number of non-surgical cosmetic procedures, the application of botox being the first most performed procedure.The application of botulinum toxin in the field of beauty began in the 1990s and was approved by ANVISA to treat dynamic wrinkles in Brazil in 2000, marketed as the Botox® brand. The Dysport® brand was approved in 2003 and the brand that was approved in 2005 was the Prosigne®. Since then, the demand and application of this method has only increased. The objective of the present work is to seek validity and safety of the application of butolinic toxin for the treatment of dynamic wrinkles and also their prevention, for aesthetic purposes.